课题基金 / 基金详情

CORE--CLINICAL TRIAL PROTOCOL REVIEW AND MONITORING SYSTEM

CORE--CLINICAL TRIAL PROTOCOL REVIEW AND MONITORING SYSTEM
核心——临床试验方案审查和监测系统
批准号:
6563724
负责人:
JOHN A GLASPY
金额:
$16.72万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-12-01 至 2002-11-30

项目摘要

项目成果

JOHN A GLASPY的其他基金

相似基金

相关文献

中文摘要
翻译
描述:内部科学议定书审查委员会,主席为 John A.Glaspy博士被有条件地批准进行早期同行重新评估 在上一次审查中。在此期间进行了两次同行审查评价 上级委员会一级的临时成员。第一个结果是不赞成; 第二,批准了ISPRC程序。当时的关键要素 财政大臣的一份备忘录表明,所有与癌症有关的研究 在加州大学洛杉矶分校完成之前,需要获得ISPRC的批准才能获得科学价值 它提交给IRB的证据以及委员会更严格的职能的证据。 此外,扩大了委员会成员,包括更广泛的 已经建立了肿瘤学学科和肿瘤学研究。一个 还建立了统计核查,以确保所有议定书 在提交之前已经被癌症中心的生物统计学家看到。 本申请提供了所有协议正在被 在IRB提交之前,每年在重新审查后重新批准。 该委员会目前由11名成员组成,分别代表生物统计学、癌症 控制、药学、研究护理和一系列肿瘤学家。对于新的 在提交议定书时,委员会使用一套标准的标准。多数 过去一年的不批准基于以下其中一项:1) 科学价值不足;2)生物统计分析不足 部分;3)与现有协议重叠,而不明显需要 二次协议;4)由于无法支持和执行协议 缺乏足够的资源。在年度续期方面,大多数 对这些延期的不批准是基于下列原因之一: 应计比率大幅低于原定目标; 应计项目总额已达到原来规定的目标;或质量报告 控制委员会的任何调查员的研究表明 研究没有以一种会导致产生 正确有效的结论。
英文摘要
Description: The Internal Scientific Protocol Review Committee, chaired by Dr. John A. Glaspy, was approved conditionally for early peer reevaluation during the last review. Two peer review evaluations occurred during the interim at the Parent Committee level. The first resulted in disapproval; the second awarded approval for the ISPRC process. The key elements at that time were a memo from the Chancellor indicating that all cancer-related research done at UCLA needed to have approval of the ISPRC for scientific merit prior to its submission to the IRB and evidence of more rigorous committee function. In addition, expanded committee membership, including a broader range of oncology disciplines and oncology research, had been instituted. A statistical checkoff had also been established to assure that all protocols have been seen by Cancer Center biostatisticians prior to their submission. The present application provides evidence that all protocols are being reapproved annually after re-review prior to the IRB submission. The committee now consists of 11 members representing biostatistics, cancer control, pharmacy, research nursing, and a spectrum of oncologists. For new protocol submissions, the committee uses a standard set of criteria. Most disapprovals over the past year are based upon one of the following: 1) insufficient scientific merit; 2) inadequate biostatistical analytical sections; 3) overlap with existing protocols without an obvious need for the secondary protocol; and 4) inability to support and carry out the protocol due to lack of adequate resources. With respect to the annual renewal, most disapprovals of those continuations were based upon one of the following: the rate of accrual is substantially lower than the originally stated target; the total accrual has met the originally stated target; or a report of the Quality Control Committee of any of the investigator's studies indicating that the research has not been conducted in a fashion that will lead to generation of correct and valid conclusions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Resource for Minority Patient Recruitment
Women's Cancers
CORE--CLINICAL TRIAL PROTOCOL REVIEW AND MONITORING SYSTEM
CORE--CLINICAL MATERIAL/PROTOCOLS
海外基金